Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
108 hedge funds and large institutions have $533M invested in Albireo Pharma Inc in 2020 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 9 closing their positions.
289% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 9
96% more capital invested
Capital invested by funds: $272M → $533M (+$261M)
42% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 26
32% more funds holding
Funds holding: 82 → 108 (+26)
86% less call options, than puts
Call options by funds: $7.05M | Put options by funds: $51.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$20.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$17.7M |
| 3 |
CAC
Cowen and Company
New York
|
+$17.5M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$14.6M |
| 5 |
SCM
Sio Capital Management
New York
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.64M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$4.61M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$2.22M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$2.14M |
| 5 |
EP
Eversept Partners
New York
|
-$2.07M |
ALBO Hedge Fund Activity: Q3 2020 in Review
108 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q3 2020, worth a combined $533M — up 96% from $272M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ALBO positions and 9 closed out — a net gain of 26 holders — while 37 added to existing stakes and 26 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $20.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $4.64M sold.
- 108 institutional investors held Albireo Pharma Inc (ALBO) as of Q3 2020, up from 82 in Q2 2020.
- Funds reported $533M of Albireo Pharma Inc stock for Q3 2020, up 96% quarter-over-quarter.
- 35 funds opened new Albireo Pharma Inc positions in Q3 2020 and 9 closed out, a net change of +26 holders.
- The largest Albireo Pharma Inc buyer in Q3 2020 was Cormorant Asset Management, an estimated $20.4M added.
- The largest Albireo Pharma Inc seller in Q3 2020 was Point72 Asset Management, an estimated $4.64M sold.
Based on aggregated 13F filings for Q3 2020.